18
Shanghai Junshi
1877.HK·HKEXShanghai CNFounded 20124,000 employees
Mid CapbiotechPublicOncologyImmunology
Platform: Toripalimab
Market Cap
$3B
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (1877.HK)
Loading 1877.HK stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 187-151 | 187-151 | Phase 1 | 1 | Aβ | ALSAS | ||
| 187-8157 | 187-8157 | Phase 2/3 | 2 | FcRn | Breast Ca | ||
| Darasacituzumab | 187-233 | Phase 2/3 | 2 | IL-13 | MDSIPF |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Shanghai Junshi trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (4)